Georgia's Online Cancer Information Center

Find A Clinical Trial

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Cancer Type
Hematopoietic Malignancies
Non-Hodgkin Lymphoma
Unknown Primary
Trial Phase
Phase II
18 Years and older, Male and Female
Study Type
Protocol IDs
ALLO-647-201 (primary)
Study Sponsor
Allogene Therapeutics


The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647
combined with fludarabine and cyclophosphamide compared to fludarabine and
cyclophosphamide alone in a lymphodepletion regimen prior to ALLO-501A CAR T therapy in
adults with relapsed or refractory large B-cell lymphoma


  1. Histologically confirmed diagnosis of relapsed/refractory large B-cell lymphoma at last relapse
  2. Relapsed or refractory disease after at least 2 lines of chemotherapy
  3. ECOG performance status 0 or 1
  4. Absence of significant donor (product)-specific anti-HLA antibodies (DSA)
  5. Adequate hematological, renal and liver function

Treatment Sites in Georgia

Winship Cancer Institute of Emory University

1365 Clifton Road NE
Building C
Atlanta, GA 30322

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.